Business Context and Reporting Period
This Form 8-K is filed by Bristol-Myers Squibb Company on August 19, 2020. The report addresses a legal matter under Item 8.01 (Other Events) concerning a Delaware Court of Chancery order in the case Landers v. Caforio, et al.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a legal notice regarding litigation settlement and does not contain financial performance data.
Material Changes
There are no material changes to financial operations reported. The filing details the finalization of a legal settlement regarding a stockholder class action lawsuit filed in February 2019 related to the company's acquisition of Celgene Corporation.
Guidance, Outlook, and Management Commentary
- Litigation Status: The Court approved a notice on August 19, 2020, regarding the settlement of the Landers lawsuit.
- Settlement Terms: Bristol-Myers Squibb agreed to pay $150,000 to the plaintiff's counsel for attorneys' fees and expenses.
- Scope of Payment: This payment is in full satisfaction of the claim for fees and expenses. The Court will not review the reasonableness of the payment.
- Background: The lawsuit alleged that directors breached fiduciary duties by failing to disclose material information regarding the Celgene merger. The company previously addressed these claims via supplemental disclosures in an April 2019 Form 8-K.
Investor Verification Checklist
- Verify the final status of the Landers v. Caforio litigation in Delaware Court of Chancery records.
- Confirm the $150,000 settlement payment has been processed and recorded in the company's financial statements.
- Review the April 4, 2019 Form 8-K to understand the supplemental disclosures that originally mooted the plaintiff's claims.
- Check for any other pending litigation related to the Celgene acquisition that may not be resolved by this specific settlement.